The study showed that all five patients averaged a steady drop in pain levels over the course of the four-week treatment, and that pain levels continued to drop when the treatment finished. Patients’ lowest pain levels occurred at a four-week follow-up, at which point they showed an averaged 45 percent drop in their pain scores. The next step following the pilot study will be a larger, controlled study that involves approximately 40 fibromyalgia patients, said device developer M. Bret Schneider, MD, during a presentation at the annual meeting of the American Psychiatric Association.
The repetitive transcranial magnetic stimulation device is comparable to a TMS device by NeuroStar, but the device uses four coils instead of one to create a pulsing magnetic field and produce an electrical current in the patient’s prefrontal cortex, said Dr. Schneider.
Related Articles on Pain Management:
UCSF Study Uses Cell Transplant Therapy to Reduce Neuropathic Pain
Nevro Receives FDA Approval to Test Spinal Cord Stimulation Device
Laser Spine Institute Launches Employee Wellness Program
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
